



Date: August 20, 2021

Subject: CATB1 Options - Expiration Pricing Consideration

CATB1 (adjusted Catabasis Pharmaceuticals, Inc. options) will be subject to special pricing consideration in expiration processing on August 20, 2021. The pricing consideration is due to the undetermined cash in lieu of fractional shares amount included in the option deliverable of CATB1 as indicated below. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

CATB1

CATB1 options are adjusted Catabasis Pharmaceuticals, Inc. options, adjusted August 20, 2021 (see OCC Information Memo #49154). The deliverable of CATB1 options is:

NEW DELIVERABLE

PER CONTRACT:

- 1) 16 (New) Catabasis Pharmaceuticals, Inc. (CATB) Common Shares
- 2) Cash in lieu of approximately 0.6667 fractional CATB Shares

As of August 20, 2021, the CATB Exchange Agent has not determined the price to be used to determine the cash in lieu amount.

For purposes of calculating a CATB1 price for use in expiration processing, OCC will use the following formula:

$$\text{CATB1} = 0.166667 (\text{CATB})$$

For example, if CATB closes at 7.32, the CATB1 price would be:

$$\text{CATB1} = 0.166667 (7.32) = 1.22$$

This formula includes an estimate for the value of the cash in lieu amount and not the actual amount applicable in the reverse split.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email investorservices@theocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.